Nektar Therapeutics (NASDAQ:NKTR) Third Quarter 2024 Results

Key Financial Results

• Revenue: US$24.1m (flat on 3Q 2023).
• Net loss: US$37.1m (loss narrowed by 19% from 3Q 2023).
• US$0.18 loss per share (improved from US$0.24 loss in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Nektar Therapeutics Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 32%. Earnings per share (EPS) also surpassed analyst estimates by 15%.

Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US.

The company's shares are up 14% from a week ago.

Risk Analysis

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.